Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
FDA phase 3 agreement for relcobatinib in chronic myeloid leukemia advances Enliven's clinical catalyst.
What changed
FDA phase 3 agreement for relcobatinib in chronic myeloid leukemia advances Enliven's clinical catalyst.
Why it matters
FDA phase 3 agreement for relcobatinib in chronic myeloid leukemia advances Enliven's clinical catalyst. — impact context not separately stored; see What changed.
← Dashboard
Oct 07, 2026 04:41 AM ET